4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}-2,3,6-trimethylphenyl acetate

• ChemBase编号: 1084
• 分子式: C17H27NO4
• 平均质量: 309.40058
• 单一同位素质量: 309.19400835
• SMILES: O(CC(O)CNC(C)C)c1c(c(c(OC(=O)C)c(c1)C)C)C
• Canonical SMILES: OC(COc1cc(C)c(c(c1C)C)OC(=O)C)CNC(C)C
• InChI: InChI=1S/C17H27NO4/c1-10(2)18-8-15(20)9-21-16-7-11(3)17(22-14(6)19)13(5)12(16)4/h7,10,15,18,20H,8-9H2,1-6H3
• InChIKey: BQIPXWYNLPYNHW-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}-2,3,6-trimethylphenyl acetate
• IUPAC传统名: metipranolol
• 商标名: Disorat; Trimepranol; OptiPranolol
• 别名: Metipranololum [INN-Latin]; Metipranolol hydrochloride; Metipranolol

登记号

• CAS号: 22664-55-7
• PubChem SID: 46505935; 160964547
• PubChem CID: 31477
• ATC码: S01ED04; C07BA68
• CHEMBL: 1291
• Chemspider ID: 29193
• DrugBank ID: DB01214
• KEGG ID: D02374
• 美国药典/FDA物质标识码: X39AL81KEB
• 维基百科标题: Metipranolol
• Medline Plus: a601078

理论计算性质

JChem

• Acid pKa: 14.087952
• 质子受体: 4
• 质子供体: 2
• LogD (pH = 5.5): -0.45148742
• LogD (pH = 7.4): 0.5165057
• Log P: 2.7417443
• 摩尔折射率: 86.6315 cm^3
• 极化性: 33.92427 Å^3
• 极化表面积: 67.79 Å^2
• 可自由旋转的化学键: 8
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 2.13
• LOG S: -3.25
• 溶解度: 1.73e-01 g/l

分子性质

理化性质

• 溶解度: 589 mg/L
• 疏水性(logP): 2.2

详细说明

DrugBank - DB01214

• Drug Groups: approved
• Description: A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent. [PubChem]
• Indication: Indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma.
• Pharmacology: Metipranolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Metipranolol is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Metipranolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Metipranolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce.
• Affected Organisms: Humans and other mammals
• External Links: Wikipedia; RxList; Drugs.com